126results about How to "Avoid cytotoxicity" patented technology

The invention relates to a preparation method of injectable natural polysaccharide self-healing hydrogel. The preparation method of the injectable natural polysaccharide self-healing hydrogel comprises the following steps: firstly synthesizing water soluble N-carboxyethyl chitosan by carrying out a Michael addition reaction on acrylic acid and chitosan, carrying out an oxidization reaction on sodium periodate and sodium alginate to obtain oxidized sodium alginate, then carrying out a dehydration condensation reaction on N-carboxyethyl chitosan and oxidized sodium alginate and on adipic dihydrazide and oxidized sodium alginate in a phosphate buffer liquid at the temperature of 37 DEG C, so as to respectively generate invertible imine bond and acylhydrazone bond, and finally preparing injectable natural polysaccharide macromolecular hydrogel with self-healing property. The preparation method of the injectable natural polysaccharide self-healing hydrogel has the advantages that a synthetic process of the injectable self-healing hydrogel is simple and green, reaction conditions are mild, the injectable self-healing hydrogel can form gel in a physiological environment and has self-healing capability, and the injectable self-healing hydrogel has a good application prospect in the fields of drug sustained release and the like.

The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and / or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

A pharmaceutical composition for preventing or treating chronic inflammatory airway diseases comprising alpha-enolase protein as an active ingredient is provided. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing chronic inflammatory airway diseases comprising alpha-enolase protein. The present invention further provides a composition for screening a therapeutic agent for chronic inflammatory airway diseases, comprising one or more of alpha-enolase protein or autoantibodies to alpha-enolase obtained from patients with chronic inflammatory airway diseases, and a method for screening a therapeutic agent for chronic inflammatory airway diseases using this composition. The present invention still further provides methods for diagnosing, preventing or treating chronic inflammatory airway diseases using alpha-enolase protein.

Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and / or radiosensitive.

The invention discloses a chitosan hydrogel. The structural unit of the chitosan hydrogel is shown in the specification; and in the structural unit, m is a natural number in a range of 400-700, and n is a natural number in a range of 30-100. The invention also discloses a preparation method of the chitosan hydrogel, and an application of the chitosan hydrogel. The method comprises the following steps: polyethylene glycol and tyramine molecules are grafted to a chitosan molecular chain in order to obtain a highly-water-soluble chitosan derivative, and the derivative is processed under the action of a crosslinking reagent to obtain the chitosan hydrogel. The process of the preparation method is simple, and the prepared chitosan hydrogel has the advantages of good physical, chemical and biological performances, good histocompatibility, environmental protection, and non-toxicity, and can be safely and effectively applied in restoration of wound tissues.

The invention provides a foreign gene-carrying recombinant virus vector efficiently produced in a packaging cell and a construction method and application thereof. The foreign gene-carrying recombinant virus vector is characterized in that at least one target point nucleotide sequence of the following micro RNA is inserted into the 3' non-translational zone of a foreign gene connected with a virus in an operable way; and the micro RNA expresses at a high level in a virus packaging cell, and does not express or expresses at a low level in a target cell. Therefore, the invention realizes the selective inhibition of the expression of the foreign gene in the virus packaging cell, avoids the negative effect of the foreign gene on the virus packaging and production, and improves the production efficiency and titer of the virus. Simultaneously, the invention can not lower the expression level of the foreign gene in the target cell, and can not affect the therapeutic effect or the research onthe function of the foreign gene.

The invention provides a whitening composition, whitening skin-brightening cream comprising the same and a preparation method thereof. The whitening skin-brightening cream is prepared from the following components in percent by mass: 0.1-20% of the whitening composition, 1-25% of a wetting agent, 1-5% of an emulsifier, 1-20% of skin-moistening grease, 0.1-5% of a skin conditioner, 0.05-3% of a permeation aid, 0.01-1% of a chelating agent, 0.1-1% of a thickener, 0-1% of essence, 0.05-2% of a preservative and the balance deionized water. The whitening composition is prepared from eight traditional Chinese medicinal material extraction solutions: ginseng, cortex mori radicis, angelica sinensis, glycyrrhiza, tea leaves, ganoderma atrum, rhodiola rosea and folium ginkgo as well as conventionalwhitening agents nicotinamide and tranexamic acid, and has the functions of whitening synergically and reducing irritation. The whitening skin-brightening cream moistens the skin and is not greasy, iseasy to absorb, and is obvious in whitening and skin-brightening effect.

The present invention relates to a composition for preventing and treating dementia and memory impairment, which contains minocycline as active ingredient. The composition of the present invention has an effect of inhibiting brain cell death and memory impairment, which are induced by amyloid beta-protein and C-terminal protein. Thus, the composition of the present invention is useful for the prevention and treatment of various dementias, including Alzheimer's disease, and the impairment of learning and memory and cognitive function.

The invention provides a non-nucleoside antiviral inhibitor, especially a benzohetercyclic compound shown by a general formula I or pharmaceutically acceptable salt or hydrate. The invention further provides a method for preparing the compound or the pharmaceutically acceptable salt or hydrate. Pharmacology tests show that the compound or salt or hydrate accepted on the pharmacy can effectively inhibit replication of HBV (hepatitis B virus) DNA (deoxyribonucleic acid) and HCV (hepatitis C virus) RNA (Ribonucleic acid), therefore, the invention further provides applications on preparing medicaments in preventing and / or treating viral infection, especially the HBV and the HCV. The general formula I is as follows.

Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and / or radiosensitive.

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

The invention belongs to the technical field of genetic engineering, particularly relates to a genome editing method based on a zymomonas mobilis endogenous CRISPR-Cas system and application thereof and aims at taking Z.mobilis 4 as a type strain and utilizing the I-F type CRISPR-Cas system coded by its genome to establish a genome editing platform. A powerful tool is provided for basic research and application research in the strain and similar cells, and the development of metabolic engineering, system biology and synthetic biology is promoted. According to the technical scheme, the genome editing method is characterized by comprising the steps of constructing a plasmid containing an artificial CRISPR expression unit; selecting a guide RNA sequence aiming at a target site; constructing aguide RNA primer sequence on the plasmid containing the artificial CRISPR expression unit; constructing a donor DNA sequence on a vector to obtain an editing plasmid; transforming the editing plasmidinto competent cells for editing.

Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.

Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1:wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1− represents an appropriate counter anion and q represents an integer of 1 or 2.

The invention discloses a culture medium capable of promoting the division growth of mesenchymal stem cells, which comprises a serum-free basic culture medium and an additive added on the basis of theserum-free basic culture medium, wherein the additive comprises a hibiscus mutabilis extract, seaweed polysaccharide, astragaloside IV, human serum albumin, transferrin, glutamine, platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and vitamin A; the hibiscus mutabilis extract has antioxidant and cell activating activity, and can effectively promote the growth of cell metabolic by compounding seaweed polysaccharide and astragaloside IV; human serum albumin, transferrin, glutamine and vitamin A provide essential nutrient substances for the growth of stem cells; platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and other cytokines together promote the rapid growth and proliferation ofstem cells; the culture medium not only can improve the growth activity of mesenchymal stem cells, shorten the culture time, promote the expression of cell growth factors, but also can maintain the stem cell activity of the differentiation potential of mesenchymal stem cells; stem cells are not differentiated in daily culture, thereby providing convenience for scientific research.

The invention belongs to the field of peptide-containing medicinal preparations, and in particular relates to polypeptide combined with various amyloid protein monomers simultaneously and application thereof, which can be applied to preparation of an antibody for identifying various amyloid protein transitional monomers, and diagnosis, treatment and test research of amyloid protein diseases. In the polypeptide combined with various amyloid protein monomers simultaneously (PEMX) provided by the invention, the amino acid sequence is shown as Cys-Trp-His-Thr-Asp-Thr-Arg-Ser-Cys; or the amino acid sequence is subjected to substitution, deficiency or addition of one or more amino acids. By the polypeptide combined with various amyloid protein monomers simultaneously and the application thereof, an organism can be effectively stimulated to generate a specific antibody combined with various amyloid protein transitional monomers, and the antibody can inhibit aggregation and cytotoxicity of amyloid protein.

Disclosed is a cyclophilin protein with PPIase activity functioning as an antioxidant. When being overexpressed in transplanted cells, the cyclophilin protein remarkably reduces the cytotoxicity induced by cyclosporin A or its analogues so that it can greatly improve the success rate in transplantation. Also, disclosed is a composition useful to prevent transplant rejection, comprising a recombinant expression vector which can over-express a cyclophilin protein with PPIase activity. The recombinant expression vector is introduced into cells which are thus transformed to be resistant to cyclosporin A and its analogues. A method of preparing such cells is also disclosed.

The invention relates to gelidium pacificum okam polysaccharide as well as a preparation method and application thereof, and belongs to the field of natural polymers. The invention provides a method for extracting and separating polysaccharide from gelidium pacificum okam, as well as a chemical structure and application of the polysaccharide. The average relative molecular weight is determined byutilizing GPC and the monosaccharide composition is analyzed by using GC-MS; the average relative molecular weight of the gelidium pacificum okam polysaccharide A-11 disclosed by the invention is found to be 28807Da and the gelidium pacificum okam polysaccharide A-11 is mainly prepared from xylose and galactose; in addition, trace amounts of rhamnose, arabinose, fucose, allose, fructose, glucose and mannose are found. Meanwhile, the gelidium pacificum okam polysaccharide A-11 disclosed by the invention has the advantages that the cytotoxicity of LPS-induced THP-1 is significantly inhibited, sothat the cells are prevented from being damaged; besides, the expression of signal factors MyD88 and TRAF-6 in an immune signaling pathway can be regulated so as to enhance human immunity.

Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.

The invention relates to a method for amplifying autologous bone marrow mesenchymal stem cells, in particular to the purpose of finding out the optimal environment for cell growth by utilizing the compound of culture media and a little of autoserum as well as the purpose of strictly controlling the cell fusion degree in the method so as to achieve the purpose of fast culturing the bone marrow mesenchymal stem cells in the end; and the use of the autoserum remedies the defects of fetal calf serum. The culture time of the bone marrow mesenchymal stem cells is greatly shortened, thereby being beneficial to clinical application. Simultaneously, the method is used for culturing the bone marrow mesenchymal stem cells, and 1.5-2*107 mesenchymal stem cells can be obtained through amplification innearly twenty days by extracting 5 ml bone marrow. The dosage of blood serum is greatly reduced, thereby reducing the quantity of blood collected from patients. The obtained bone marrow mesenchymal stem cells have the characteristics of the stem cells in the aspects of cell morphology, growth cycle, phenotype, inducing differentiation capacity, and the like.

The invention belongs to the technical field of genetic engineering, and in particular, relates to a method for highly efficiently deleting large fragments of a genome based on an endogenous CRISPR-Cas system of zymomonas mobilis and an application thereof. The method includes the steps: constructing a plasmid containing an artificial CRISPR expression unit; determining a large-fragment editing target site, selecting a guideRNA sequence for the editing target site and designing a primer; constructing the guideRNA primer sequence to the plasmid containing the artificial CRISPR expression unit,and constructing a vector; constructing a donor DNA sequence to the vector, to obtain an editing plasmid; and transforming the editing plasmid into a receptive cell, and editing. With a high-throughput gene editing platform based on the endogenous CRISPR-Cas system of zymomonas mobilis, the editing purpose of deleting the large fragments of the genome of the strain is achieved, and the developmentof metabolic engineering, system biology and synthetic biology is promoted.

The invention belongs to the field of medical materials for tendon injury repair and discloses a polycaprolactone / methylacryloyl elastin nanofiber composite membrane and a preparation method and application thereof. The preparation method specifically comprises the following steps of grafting methacrylic anhydride to elastin to obtain the methylacryloyl elastin; then mixing polycaprolactone with the methylacryloyl elastin uniformly to prepare a spinning solution; carrying out electrostatic spinning by using the spinning solution to obtain a composite membrane; and soaking the composite membrane by using a photoinitiator solution, carrying out photo-crosslinking under ultraviolet light and then carrying out washing and drying for many times to obtain the polycaprolactone / methylacryloyl elastin nanofiber composite membrane. The preparation method is easy to operate and relatively low in production cost, and the obtained composite membrane is good in mechanical property and biocompatibility and can be used for tendon tissue engineering and tissue repair.

The invention provides a foreign gene-carrying recombinant virus vector efficiently produced in a packaging cell and a construction method and application thereof. The foreign gene-carrying recombinant virus vector is characterized in that at least one target point nucleotide sequence of the following micro RNA is inserted into the 3' non-translational zone of a foreign gene connected with a virus in an operable way; and the micro RNA expresses at a high level in a virus packaging cell, and does not express or expresses at a low level in a target cell. Therefore, the invention realizes the selective inhibition of the expression of the foreign gene in the virus packaging cell, avoids the negative effect of the foreign gene on the virus packaging and production, and improves the production efficiency and titer of the virus. Simultaneously, the invention can not lower the expression level of the foreign gene in the target cell, and can not affect the therapeutic effect or the research onthe function of the foreign gene.

The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

Disclosed is an artificial bone material having controlled calcium ion elution, which does not induce cytotoxicity or any inflammatory response. It is found that the elution of a calcium ion from an artificial bone material for transplantation which contains a calcium-containing substance can be prevented effectively by subjecting the carrier to a surface treatment or adding a surface-treating agent to the carrier. It is also found that the induction of cytotoxicity can be prevented and the induction of an inflammatory response can also be prevented by using the above-mentioned carrier having controlled calcium ion elution.